芬戈利莫德通过AMPK/mTOR途径调节自和神经元亡,缓解与2型糖尿病相关的认知衰退
Jie Li1, Mingjie Yin1, Zhen Wang2
1Department of Internal Medicine, Hebei Medical University, Shijiazhuang 050000, China.
Brain research
|September 16, 2024
概括
芬戈利莫德 (FTY720) 通过增强自和通过AMPK/mTOR途径抑制亡,在不改变血糖水平的情况下,改善了认知功能,并减少了2型糖尿病小鼠的海马损伤.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病与认知能力下降有关.
- 芬戈利莫德 (FTY720) 是一种具有潜在神经保护性能的免疫调节剂.
- FTY720在糖尿病相关认知功能障碍中的作用需要进一步研究.
研究的目的:
- 调查fingolimod (FTY720) 对2型糖尿病小鼠模型认知衰退的影响.
- 探索FTY720的潜在神经保护机制,重点关注自,亡以及AMPK/mTOR信号通路.
主要方法:
- 在小鼠中诱导了2型糖尿病,使用高脂肪饮食和链毒素.
- 小鼠接受了不同剂量的FTY720治疗,持续了8周.
- 用莫里斯水迷宫和新的物体识别测试来评估认知功能.
- 分析了海马组织的病理变化,蛋白质表达 (自,亡,AMPK/mTOR通路) 和神经元超结构.
主要成果:
- 在2型糖尿病小鼠中,FTY720治疗显著改善了认知功能,并减少了海马的损伤.
- FTY720调节了与自相关的蛋白质 (LC3 II/I比率增加,Beclin-1;P62减少) 和与亡相关的蛋白质 (Bax减少,Bcl-2增加) 的表达.
- FTY720影响了AMPK/mTOR信号通路,并没有影响体重或禁食血糖水平.
结论:
- 芬戈利莫德 (FTY720) 在2型糖尿病相关的认知衰退中显示出显著的神经保护作用.
- FTY720增强海马体自和抑制细胞亡,可能通过AMPK/mTOR信号通路进行介导.
- FTY720代表了2型糖尿病认知障碍的潜在治疗剂,独立于血糖控制.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
108
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Psychoneuroimmunology: Diabetes and Cancer
26
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
26


